Oaktree Acquisition Corp. III Life Sciences Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing December 16, 2024
Oaktree Acquisition Corp. III Life Sciences announced that starting December 16, 2024, holders of units from its initial public offering can separately trade Class A ordinary shares and warrants. Units will continue trading on Nasdaq as 'OACCU', while separated Class A shares and warrants will trade under 'OACC' and 'OACCW' respectively.
To separate units, holders must contact Continental Stock Transfer & Trust Company. Only whole warrants will trade, with no fractional warrants issued. The initial offering was underwritten by Jefferies , Citigroup Global Markets Inc., and UBS Investment Bank as joint book-running managers. The SEC declared the registration statement effective on October 23, 2024.
Oaktree Acquisition Corp. III Life Sciences ha annunciato che a partire dal 16 dicembre 2024, i detentori di unità della sua offerta pubblica iniziale possono negoziare separatamente le azioni ordinarie di Classe A e i warrant. Le unità continueranno a essere negoziate su Nasdaq come 'OACCU', mentre le azioni di Classe A e i warrant separati saranno scambiati rispettivamente con 'OACC' e 'OACCW'.
Per separare le unità, i detentori devono contattare la Continental Stock Transfer & Trust Company. Solo i warrant interi saranno negoziati, senza emissioni di warrant frazionari. L'offerta iniziale è stata sottoscritta da Jefferies, Citigroup Global Markets Inc. e UBS Investment Bank in qualità di gestori di book-running congiunti. La SEC ha dichiarato efficace la dichiarazione di registrazione il 23 ottobre 2024.
Oaktree Acquisition Corp. III Life Sciences anunció que a partir del 16 de diciembre de 2024, los titulares de unidades de su oferta pública inicial podrán negociar separadamente las acciones ordinarias de Clase A y los warrants. Las unidades seguirán negociándose en Nasdaq con el símbolo 'OACCU', mientras que las acciones de Clase A y los warrants separados se negociarán bajo 'OACC' y 'OACCW', respectivamente.
Para separar las unidades, los titulares deben contactar a Continental Stock Transfer & Trust Company. Solo se intercambiarán warrants enteros, sin emisión de warrants fraccionarios. La oferta inicial fue suscrita por Jefferies, Citigroup Global Markets Inc. y UBS Investment Bank como co-gestores de libro. La SEC declaró efectiva la declaración de registro el 23 de octubre de 2024.
Oaktree Acquisition Corp. III Life Sciences는 2024년 12월 16일부터 최초 공개 공모에서 발행된 유닛 보유자가 A급 보통주와 워런트를 별도로 거래할 수 있다고 발표했습니다. 유닛은 'OACCU'라는 이름으로 Nasdaq에서 계속 거래되며, 분리된 A급 주식과 워런트는 각각 'OACC'와 'OACCW'라는 이름으로 거래됩니다.
유닛을 분리하기 위해서는 보유자가 Continental Stock Transfer & Trust Company에 문의해야 합니다. 전체 워런트만 거래되며, 분할 워런트는 발행되지 않습니다. 초기 공모는 Jefferies, Citigroup Global Markets Inc. 및 UBS Investment Bank가 공동 주관하였습니다. SEC는 2024년 10월 23일에 등록 성명을 효력을 발휘한다고 발표했습니다.
Oaktree Acquisition Corp. III Life Sciences a annoncé qu'à partir du 16 décembre 2024, les détenteurs d'unités de son introduction en bourse pourront échanger séparément des actions ordinaires de Classe A et des bons de souscription. Les unités continueront à être échangées sur le Nasdaq sous le symbole 'OACCU', tandis que les actions de Classe A et les bons de souscription séparés seront échangés sous 'OACC' et 'OACCW', respectivement.
Pour séparer les unités, les détenteurs doivent contacter la Continental Stock Transfer & Trust Company. Seuls des bons de souscription entiers seront échangés, sans émission de bons de souscription fractionnaires. L'offre initiale a été souscrite par Jefferies, Citigroup Global Markets Inc. et UBS Investment Bank en tant que co-managers. La SEC a déclaré la déclaration d'enregistrement efficace le 23 octobre 2024.
Oaktree Acquisition Corp. III Life Sciences gab bekannt, dass ab dem 16. Dezember 2024 Inhaber von Einheiten aus ihrem Börsengang die Klasse A Stammaktien und Warrants separat handeln können. Die Einheiten werden weiterhin an der Nasdaq unter dem Tickersymbol 'OACCU' gehandelt, während die separaten Klasse A Aktien und Warrants unter den Symbolen 'OACC' und 'OACCW' gehandelt werden.
Um die Einheiten zu trennen, müssen die Inhaber die Continental Stock Transfer & Trust Company kontaktieren. Es werden nur ganze Warrants gehandelt, es werden keine fractional Warrants ausgegeben. Das anfängliche Angebot wurde von Jefferies, Citigroup Global Markets Inc. und UBS Investment Bank als gemeinsame Book-Running-Manager gezeichnet. Die SEC erklärte die Registrierungsanmeldung am 23. Oktober 2024 für wirksam.
- Increased trading flexibility for investors through separate trading of shares and warrants
- Listing on major exchange (Nasdaq) providing good liquidity
- Strong underwriting support from major financial institutions
- No fractional warrants will be issued, potentially limiting smaller investors
- Additional administrative steps required for unit separation
The units were initially offered by the Company in an underwritten offering, in which Jefferies LLC, Citigroup Global Markets Inc., and UBS Investment Bank served as the joint book-running managers. The registration statement relating to the securities sold in the underwritten offering was declared effective on October 23, 2024 by the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from: Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor,
About Oaktree Acquisition Corp. III Life Sciences
Oaktree Acquisition Corp. III Life Sciences is the third public acquisition vehicle sponsored by an affiliate of Oaktree Capital Management, L.P. (“Oaktree”) and follows the successfully completed mergers between Oaktree Acquisition Corp. and Hims & Hers (a direct-to-consumer healthcare business) and between Oaktree Acquisition Corp. II and Alvotech (a global biosimilars business). The Company leverages Oaktree’s expertise in the life sciences sector, where as of November 30, 2024, the firm has committed approximately
About Oaktree
Oaktree is a leader among global investment managers specializing in alternative investments, with
Cautionary Note Concerning Forward-Looking Statements
This press release, and oral statements made from time to time by representatives of the Company, may include statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding possible business combinations, the financing thereof and the anticipated use of the net proceeds from the initial public offering, and matters related to the foregoing, as well as all other statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the filings that the Company made or will make with the SEC. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions and risks, many of which are beyond the control of the Company, including those set forth in the “Risk Factors” section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. An investment in the Company is not an investment in Oaktree. Past experience or performance by our management team or their affiliates, including Oaktree, Oaktree Acquisition Corp. and Oaktree Acquisition Corp. II, may not be indicative of future performance of an investment in us. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211880325/en/
Investor:
info@oaktreeacquisitioncorp.com
Media:
John Christiansen/Monique Sidhom
FGS Global
Oaktree@fgsglobal.com
Source: Oaktree Acquisition Corp. III Life Sciences
FAQ
When will OACCU shares and warrants begin trading separately?
What are the new trading symbols for OACCU components after separation?
How can OACCU unit holders separate their units into shares and warrants?
When was the OACCU registration statement declared effective by the SEC?
Which investment banks served as underwriters for the OACCU offering?
